Bone Biologics Corporation (BBLG)
- Previous Close
1.5500 - Open
1.5300 - Bid --
- Ask --
- Day's Range
1.5100 - 1.6099 - 52 Week Range
1.4600 - 72.0000 - Volume
28,154 - Avg. Volume
82,152 - Market Cap (intraday)
1.345M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-34.0100 - Earnings Date May 6, 2024 - May 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.50
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
www.bonebiologics.comRecent News: BBLG
Performance Overview: BBLG
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBLG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBLG
Valuation Measures
Market Cap
1.35M
Enterprise Value
-1.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-96.34%
Return on Equity (ttm)
-202.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.95M
Diluted EPS (ttm)
-34.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.03M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.21M